Rubius Therapeutics, Inc.

OTCPK:RUBY Stock Report

Market Cap: US$5.2m

Rubius Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Rubius Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03

Aug 09

Rubius: Poor Data, Punishing Environment, Beaten Stock

Jun 19

Rubius Looks Attractive Before AACR Data Readout

Mar 21

Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Oct 28
Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Our Read On Rubius Therapeutics

Jul 11

Rubius Therapeutics EPS beats by $0.02

May 10

Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Feb 25
Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Rubius Therapeutics EPS misses by $0.01

Nov 09

Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

Oct 28

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rubius Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:RUBY - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2022N/A-180-155-150N/A
9/30/2022N/A-215-161-155N/A
6/30/2022N/A-201-159-153N/A
3/31/2022N/A-207-159-154N/A
12/31/2021N/A-197-149-145N/A
9/30/2021N/A-182-142-138N/A
6/30/2021N/A-174-136-133N/A
3/31/2021N/A-162-130-126N/A
12/31/2020N/A-168-133-128N/A
9/30/2020N/A-172-144-126N/A
6/30/2020N/A-178-153-126N/A
3/31/2020N/A-179-167-128N/A
12/31/2019N/A-163-151-110N/A
9/30/2019N/A-146-132-101N/A
6/30/2019N/A-126-121-90N/A
3/31/2019N/A-107-89-70N/A
12/31/2018N/A-89-73-58N/A
9/30/2018N/A-80-60-48N/A
6/30/2018N/A-65-38-35N/A
3/31/2018N/A-54-33-30N/A
12/31/2017N/A-45-24-22N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RUBY's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if RUBY's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if RUBY's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RUBY's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if RUBY's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RUBY's Return on Equity is forecast to be high in 3 years time


Discover growth companies